Standard dose of Intravitreal Aflibercept is effective in th
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to compare the effectiveness of 0.4 mg/0.01 ml (“low dose”) and 1 mg/0.025 ml (“standard dose”) intravitreal aflibercept (IVA) in the treatment of retinopathy of prematurity (ROP).

The medical history of patients treated with IVA for type 1 or aggressive posterior retinopathy of prematurity (AP-ROP) who received the lower dose (low-dose group) or the more widely used dose (standard-dose group) were reviewed retrospectively. At the last test, the clinical characteristics, regression and recurrence rates, additional therapies, retinal detachment rates, and border of vascularization were all examined.

Results:
--A total of 32 eyes of 16 patients in the low-dose group and 42 eyes of 21 patients in the standard-dose group were included.

--At the time of the initial treatment, vascularization was in zone I in 26 eyes in the low-dose group and in 14 eyes in the standard-dose group.

--The regression rate was 94% and 100%, respectively. Retinal detachment occurred in 1 unresponsive eye in the low-dose group and 2 eyes after reactivation in the standard-dose group.

--Recurrence was observed in 9 eyes in the low-dose group and 10 eyes in the standard-dose group after the complete regression of the disease with treatment.

--At 6 months, vascularization had entered zone III in 12 eyes (38%) in the low-dose group and in 24 eyes (57%) in the standard-dose group.

In particular, while the difference between groups was not statistically important, only the low-dose group had eyes that did not respond.

Source: https://www.jaapos.org/article/S1091-8531(21)00088-4/fulltext?rss=yes
Like
Comment
Share